amiloride has been researched along with MS (Multiple Sclerosis) in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chandran, S; Chataway, J; Connick, P; de Angelis, F; Foley, P; Parker, RA; Weir, CJ; Young, C | 1 |
| Barkhof, F; Bastow, R; Braisher, M; Chandran, S; Chataway, J; Connick, P; Cranswick, G; De Angelis, F; Doshi, A; Gandini Wheeler-Kingshott, CA; Giovannoni, G; Hawkins, C; John, N; MacManus, D; Ourselin, S; Parker, RA; Pavitt, SH; Plantone, D; Prados Carrasco, F; Ross, M; Sharrack, B; Stallard, N; Stutters, J; Weir, CJ | 1 |
| Craner, M; Elston, J; Evangelou, N; Fugger, L; Gerry, S; Kennard, C; Kong, Y; McKee, JB; Palace, J | 1 |
| Attfield, K; Craner, MJ; Esiri, M; Etzensperger, R; Friese, MA; Fugger, L; Newcombe, J; Vergo, S | 1 |
| Hviid, A; Melbye, M; Nielsen, NM; Pasternak, B; Svanström, H | 1 |
| Craner, MJ; Etzensperger, R; Friese, MA; Fugger, L; Vergo, S; Vincent, A; Welsh, MJ; Wemmie, JA | 1 |
3 trial(s) available for amiloride and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
Topics: Adult; Amiloride; Double-Blind Method; Fluoxetine; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neuralgia; Riluzole | 2022 |
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Topics: Administration, Oral; Adult; Amiloride; Brain; Disease Progression; Double-Blind Method; Female; Fluoxetine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Riluzole; Treatment Outcome | 2020 |
Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.
Topics: Adolescent; Adult; Amiloride; Diuretics; Double-Blind Method; England; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Neuroprotective Agents; Optic Neuritis; Quality of Life; Research Design; Retina; Tomography, Optical Coherence; Visual Acuity; Young Adult | 2015 |
3 other study(ies) available for amiloride and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
Topics: Acid Sensing Ion Channels; Aged; Amiloride; Animals; Axons; Cell Culture Techniques; Demyelinating Diseases; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Mice; Mice, Inbred C57BL; Middle Aged; Multiple Sclerosis; Nerve Tissue Proteins; Neuroprotective Agents; Oligodendroglia; Optic Nerve; Sodium Channels; Spinal Cord; Up-Regulation | 2011 |
Use of amiloride and multiple sclerosis: registry-based cohort studies.
Topics: Adult; Aged; Amiloride; Cohort Studies; Comorbidity; Diuretics; Female; Hospitalization; Humans; Male; Middle Aged; Multiple Sclerosis; Registries; Residence Characteristics; Thiazides | 2012 |
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.
Topics: Acid Sensing Ion Channels; Amiloride; Animals; Autoimmunity; Axons; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; Inflammation; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Transgenic; Multiple Sclerosis; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Sodium Channels; Spinal Cord | 2007 |